The Emirates Drug Establishment (EDE) has approved Lipfendra, a new oral treatment for adults with elevated low-density lipoprotein (LDL-C) cholesterol. The decision makes the UAE the second nation in the world to grant regulatory approval for the drug.
Lipfendra is a daily prescription medication intended for use alongside a balanced diet and regular physical activity. It targets "bad" cholesterol, a primary contributor to cardiovascular diseases, and offers a therapeutic option for patients requiring additional intervention, including those with inherited hypercholesterolaemia.
The regulatory body confirmed that the rapid authorisation was facilitated through the UAE's accelerated evaluation framework for advanced therapeutics. The mechanism aims to streamline patient access to breakthrough pharmaceuticals without compromising safety assessments.
For patients and healthcare providers in Dubai and Abu Dhabi, this approval grants early access to specialised treatment protocols that remain unavailable in most international markets.